An international clinical trial was held on the problem of breast cancer among young women. Researchers have found a new drug which improved the survival rate in young women suffering from the common type of breast cancer. In a meeting at the American Society of Clinical Oncology, Chicago the results of the test were presented. It showed the new drug has increased the survival rate by 70%. Patients who were given the drug had increased mortality rate to 29 percent.
Sara Hurvitz, the lead author of the study stated the two-thirds of breast cancer in women is an estrogen-fueled form of cancer and their focus is also on the same. Normally this breast cancer is treated in the form of therapies that block the hormone estrogen’s production. In the study, more than 670 cases were taken who had 4th stage cancer and didn’t take any prior treatment. It showed the drug increased survival rate of those who had advanced breast cancer. The name of the drug was Ribociclib or Kisqali, it is marketed by Novartis and it should be taken daily for 21 days as a pill. For seven days the patients were set off to allow their body to recover. This 28 days course costs $12,553, majority of the US people are benefited by their insurance policies.
Tags : #BreastCancer #CancerDrug #BreastCancerDrug #Ribociclib #Kisqali